We are very happy to annouce that our collaboration study led by Dr. Seung Kim (Professor in the Department of Developmental Biology at Stanford University), aiming at developing an immunocompetent B6 RIP-DTR mouse model permitting diabetes induction with 100% penetrance, was published.
These inbred mice harbor the H2b major histocompatibility complex (MHC), selectively express high affinity human diphtheria toxin receptor (DTR) in islet β-cells, and are homozygous for the Ptprca (CD45.1) allele rather than wild-type Ptprcb (CD45.2). β cell-specific expression of a high-affinity receptor for diphtheria toxin (due to RIP-DTR transgene) permits experimental β cell ablation and diabetes induction after DT administration. Using this line, diabetes reversal for over one year was achieved after transplantation with congenic C57BL/6J islets, but not with MHC-mismatched BALB/c islets, which were rapidly rejected.
Continue your reading here:
Islet cell replacement and transplantation immunology in a mouse strain with inducible diabetes
Authors: Bhagchandani P, Chang CA, Zhao W, Ghila L, Herrera PL, Chera S and Seung K Kim
Scientific Reports 12, 9033 (2022)
DOI information: https://doi.org/10.1038/s41598-022-13087-3